相关实验视频

Updated: May 13, 2025

Production of Human CRISPR-Engineered CAR-T Cells

Production of Human CRISPR-Engineered CAR-T Cells

Published on: March 15, 2021

克里斯普尔/Cas9技术修改免疫检查点在CAR-T细胞治疗的血液形成性恶性瘤

Forough Shams^1,2, Elham Sharif³, Hajar Abbasi-Kenarsari⁴

¹Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, 1968917313, Tehran, Iran.

Current gene therapy

|April 15, 2025

概括

血液性恶性瘤是血液形成组织的癌症. 通过CRISPR/Cas9基因组编辑增强的免疫检查点阻塞 (ICB) 和CAR-T细胞疗法等先进疗法为这些癌症提供了新的治疗途径.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
遗传学是一个遗传学.

背景情况:

血液性恶性瘤是由血液形成中断引起的,导致未成熟的细胞积累.
免疫向疗法,包括免疫检查点阻塞 (ICB) 和CAR-T细胞疗法,代表了癌症治疗的重大进展.

研究的目的:

探索CRISPR/Cas9技术对血液恶性瘤CAR-T细胞疗法的革命性影响.
突出基因工程和基于免疫的策略之间的协同作用,以改善癌症治疗.

主要方法:

使用免疫检查点封锁 (ICB) 针对CTLA-4,PD-1和PDL1.
使用化学抗原受体T (CAR-T) 细胞疗法,对T细胞进行基因修饰.
利用聚类正规间隔短时间的Palindromic重复 (CRISPR) /Cas9系统进行精确的基因组工程.

主要成果:

克里斯普尔/卡斯9增强了CAR-T细胞疗法的疗效,通过提高抵抗免疫逃逸的抵抗力和减少非标毒性.
对T细胞的基因改造对于开发强大的CAR-T细胞来抵抗血液癌症至关重要.
针对免疫检查点导致了许多FDA批准,改变了治疗范式.

结论:

克里斯普尔/Cas9已经彻底改变了基于免疫检查点的CAR-T细胞治疗血液性恶性瘤的方法.
持续的研究和临床试验对于进一步的进展和改善患者治疗结果至关重要.

关键词:

在CAR-T细胞疗法中.这就是CRISPR/Cas9的作用.工程T细胞的工程T细胞.血液性恶性瘤. 血液性恶性瘤.免疫检查点是一个检查点.

更多相关视频

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

Published on: July 22, 2019

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

相关概念视频

CRISPR

CRISPR

Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...

CRISPR and crRNAs

CRISPR and crRNAs

Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...